The EURION Cluster Group was launched on 31st January 2019 at the European Commission in Brussels. The event brought together all eight projects from the Call ‘New Testing and Screening Methods to Identify Endocrine Disrupting Chemicals (EDCs)’. In the European Union (EU), new and improved approaches are needed to increase the quality, efficiency and effectiveness of existing methods to meet demanding and evolving regulatory requirements worldwide. In consultation with relevant regulatory bodies, EURION research should improve and harmonise screening and testing protocols/strategies and risk assessments by developing better and faster testing tools, methods and models, including in vitro and in vivo tests, high-throughput and in silico methods (e.g. QSAR), potentially combined with research on adverse outcomes pathways (AOPs). The eight projects are focusing on the most urgent regulatory needs e.g. methods addressing the thyroid axis, developmental neurotoxicity, metabolic disorders, female reproduction and non-genotoxic carcinogenicity.
For more information related to this news item please visit:
Communication from the Commission to the European Parliament and the Council on endocrine disruptors and the draft Commission acts setting out scientific criteria for their determination in the context of the EU legislation on plant protection products and biocidal products